Organon (OGN) Liabilities from Discontinued Operations (2020 - 2025)
Organon (OGN) posted quarterly Liabilities from Discontinued Operations of 32000000.0 for Q4 2025, down 56.16% on a QoQ basis from 73000000.0 in Q1 2021.
Organon (OGN) Liabilities from Discontinued Operations (2020 - 2025) Analysis & Trends
Organon has reported Liabilities from Discontinued Operations for 3 years, with the latest figure at 32000000.0 in Q4 2025.
- Liabilities from Discontinued Operations for Q4 2025 came in at 32000000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 32000000.0 (changed N/A YoY), and the FY2025 annual result was 32000000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations retreated to 32000000.0 in Q4 2025, from 73000000.0 in the prior quarter.
- Over five years, Liabilities from Discontinued Operations peaked at 73000000.0 in Q1 2021 and troughed at 32000000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.00 Mn |
| Dec 31, 2025 | 2.00 Mn |
| Mar 31, 2021 | 73.00 Mn |
| Mar 31, 2021 | 73.00 Mn |
| Dec 31, 2020 | 128.00 Mn |
| Dec 31, 2020 | 128.00 Mn |